Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squi...(reased in the U.S. to $1139 millio...)

million in the first quarter of 2008 from $787 million in the same

period in 2007. The comparison to the first quarter 2007 sales reflects

the adverse impact of generic competition for PLAVIX(R) in 2007, which

the company estimates to be in the range of $200 million to $250

million. Estimated total U.S. prescription demand for clopidogrel

bisulfate (branded and generic) increased by 4% in the first quarter of

2008 compared to 2007. Estimated total U.S. prescription demand for

branded PLAVIX(R) increased by 78% in the same period.

-- Total revenue for ABILIFY(R), an agent for the treatment of

schizophrenia, bipolar disorders and major depressive disorder,

increased 24% to $454 million in the first quarter of 2008 from $366

million in the same period in 2007. U.S. sales increased 19% to $348

million in the first quarter 2008 from $293 million in the same period

in 2007, primarily due to higher demand. Estimated total U.S.

prescription demand increased approximately 14% compared to the same

period last year. International sales increased 45%, including a 16%

favorable foreign exchange impact, to $106 million in the first quarter

of 2008 from $73 million in the same period in 2007, due to continued

growth across European markets. Total revenue for ABILIFY(R) primarily

consists of alliance revenue representing the company's 65% share of

net sales in countries where it copromotes with Otsuka Pharmaceutical

Co., Ltd.

-- Sales of AVAPRO(R)/AVALIDE(R), an angiotensin II receptor blocker for

the treatment of hypertension, also part of the sanofi-aventis

alliance, increased 13%, including a 6% favorable foreign exchange

impact, to $305 million in the first quarter of 2008 from $270 million

in the same period in 20
'/>"/>